Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: For 12 months after approvement by the University of Yonsei institutional review board, of the 59 patients older than 20 years referred to our medical center for EUS-FNA or FNB, all consecutive pancreatic lesions were evaluated for inclusion in our prospective study. The inclusion criteria for this study were the following: diagnosed or suspected solid pancreatic masses according to clinical evaluation and imaging studies with need of histologic tissue confirmation by EUS-FNA or EUS-FNB. The exclusion criteria were the following: cystic pancreatic lesions, patients haemodynamically unstable or with severe coagulopathy (international normalized ratio \[INR\] \> 1.5 or platelet count \< 50,000 cells/cubic millimeter \[cmm3\]), patients unable to suspend anticoagulant/anti-platelet therapy, pregnancy, inability or refusal to give informed consent, and refusal to participate in the study. Patients undergoing anticoagulant or anti- platelet therapy for non-critical problems discontinued treatment at least 5 days before the endoscopic procedure. Written informed consent was obtained from all patients for the procedures performed and participation in the study, and the study protocol was approved by the University of Yonsei institutional review board. All patients were underwent the procedure under conscious sedation with propofol and midazolam according to the current guidelines.8 After procedure, the patients were monitored for at least six hours in order to immediately detect post-procedural complications and were followed for up to 7 days in order to detect late complications.


Options:
A: Arm Label: Lymph nodes, pancreatic masses & cysts; Type: OTHER; Interventions: Procedure: EUS-FNA, Device: nCLE | Intervention Type: PROCEDURE; Name: EUS-FNA; Assigned to Arm(s): Lymph nodes, pancreatic masses & cysts | Intervention Type: DEVICE; Name: nCLE; Assigned to Arm(s): Lymph nodes, pancreatic masses & cysts
B: Arm Label: 22G ProCore biopsy needle; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 22G ProCore biopsy needle | Arm Label: 22G standard FNA needle; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 22G standard FNA needle | Intervention Type: PROCEDURE; Name: 22G ProCore biopsy needle; Assigned to Arm(s): 22G ProCore biopsy needle | Intervention Type: PROCEDURE; Name: 22G standard FNA needle; Assigned to Arm(s): 22G standard FNA needle
C: Arm Label: EUS-FNB with 25-gauge; Type: EXPERIMENTAL; Interventions: Device: EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland) | Intervention Type: DEVICE; Name: EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland); Assigned to Arm(s): EUS-FNB with 25-gauge
D: Arm Label: EUS FNA with 2 passes; Type: ACTIVE_COMPARATOR; Interventions: Procedure: EUS FNA with 2 passes | Arm Label: EUS FNA with 4 passes; Type: ACTIVE_COMPARATOR; Interventions: Procedure: EUS FNA with 4 passes | Intervention Type: PROCEDURE; Name: EUS FNA with 2 passes; Assigned to Arm(s): EUS FNA with 2 passes | Intervention Type: PROCEDURE; Name: EUS FNA with 4 passes; Assigned to Arm(s): EUS FNA with 4 passes

Answer: C